Global Hairy Cell Leukemia Market Size study & Forecast, by Therapy (Chemotherapy and Targeted Therapy) and Regional Analysis, 2022-2029

Global Hairy Cell Leukemia Market Size study & Forecast, by Therapy (Chemotherapy and Targeted Therapy) and Regional Analysis, 2022-2029

The global Hairy Cell Leukemia Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2029. Hairy Cell Leukemia is a type of cancer in which the bone marrow produces an excessive number of lymphocytes. It is a blood and bone marrow malignancy. It remains stable for years and creates infections. The Hairy Cell Leukemia market is expanding because of factors such as the rising prevalence of leukemia and growing diagnosis rate in the forecast period.

According to the American Cancer Society's 2022 data, nearly 60,650 new cases of leukemia (all types) are expected to be diagnosed in 2022, with chronic lymphocytic leukemia (CLL) accounting for approximately 20,160 new cases. Furthermore, according to the same source, CLL accounts for roughly one-quarter of newly diagnosed cases of leukemia. Furthermore, according to NORD data for 2021, approximately 6,000 people are affected by hairy cell leukemia, with 600-800 new cases diagnosed in the United States each year. Whereas rising spending towards the advancement of cancer treatment and growing R&D activities by market players create lucrative opportunities for the market. However, a lack of awareness and limited health services hamper the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Hairy Cell Leukemia Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing geriatric population, and growing prevalence of chronic lymphocytic leukemia. Whereas North America is expected to grow with the highest CAGR during the forecast period, owing to factors such as increasing demand spending on research and development and growing pharmaceutical spendings.

Major market players included in this report are:
Amgen Inc.
AstraZeneca PLC
Gilead Sciences
F. Hoffmann-La Roche Ltd
Astellas Pharma
Johnson & Johnson
Merck KGaA
Biogenomics Limited
AbbVie Inc.
Pfizer Inc.

Recent Developments in the Market:
 In August 2022, AstraZeneca's Calquence tablet was approved by the FDA for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and previously treated relapsed or refractory mantle cell lymphoma (MCL).
 In May 2022, The University of Giessen conducted a Phase II/III clinical study to evaluate the efficacy and side effects of one cycle of subcutaneous cladribine treatment in patients with hairy cell leukemia.

Global Hairy Cell Leukemia Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Therapy, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters to detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Therapy:
Chemotherapy
Targeted Therapy

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Amgen Inc.
AstraZeneca PLC
Gilead Sciences
F. Hoffmann-La Roche Ltd
Astellas Pharma
Johnson & Johnson
Merck KGaA
Biogenomics Limited
AbbVie Inc.
Pfizer Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.